| [1] |
中华医学会皮肤性病学分会银屑病专业委员会. 中国银屑病诊疗指南(2018完整版)[J]. 中华皮肤科杂志, 2019, 52(10):667-710.
|
| [2] |
丁晓岚, 王婷琳, 沈佚葳, 等. 中国六省市银屑病流行病学调查[J]. 中国皮肤性病学杂志, 2010, 24(7):598-601.
|
| [3] |
王晓晖. 西南4省市银屑病流行病学调查研究[J]. 哈尔滨医药, 2017, 37(5):426-427.
|
| [4] |
Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics[J]. J Am Acad Dermatol, 2019, 80(4):1029-1072.
doi: S0190-9622(18)33001-9
pmid: 30772098
|
| [5] |
Smith CH, Yiu ZZN, Bale T, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update[J]. Br J Dermatol, 2020, 183(4):628-637.
doi: 10.1111/bjd.19039
URL
|
| [6] |
Samarasekera E, Sawyer L, Parnham J, et al. Assessment and management of psoriasis: summary of NICE guidance[J]. BMJ, 2012, 345:e6712.
doi: 10.1136/bmj.e6712
URL
|
| [7] |
NICE pathways. 2020 Musculoskeletal conditions overview[R/OL].(2020-02-25) http://pathways.nice.org.uk/pathways/musculoskeletalconditions#content=view_node%3Anodes-psoriatic-arthritis&path=view%3A/pathways/musculoskeletal_conditions/arthritis.xml In, Vol. [Accessed 26th February 2020].
|
| [8] |
Samarasekera EJ, Smith CH, National Institute of Health and Care Excellence, et al. Psoriasis: guidance on assessment and referral[J]. Clin Med (Lond), 2014, 14(2):178-182.
|
| [9] |
Eworuke E, Panucci G, Goulding M, et al. Use of tumor necrosis factor-alpha inhibitors during pregnancy among women who delivered live born infants[J]. Pharmacoepidemiol Drug Saf, 2019, 28(3):296-304.
doi: 10.1002/pds.4695
pmid: 30430682
|
| [10] |
Ferreira C, Azevedo A, Nogueira M, et al. Management of psoriasis in pregnancy - a review of the evidence to date[J]. Drugs Context, 2020, 9:2019-11-6.
|
| [11] |
中华医学会皮肤性病学分会, 中国医师协会皮肤科医师分会, 中国中西医结合学会皮肤性病专业委员会. 中国银屑病生物治疗专家共识(2019)[J]. 中华皮肤科杂志, 2019, 52(12):863-871.
|
| [12] |
Motaparthi K, Stanisic V, Van Voorhees AS, et al. From the Medical Board of the National Psoriasis Foundation: recommendations for screening for hepatitis B infection prior to initiating anti-tumor necrosis factor-alfa inhibitors or other immunosuppressive agents in patients with psoria-sis[J]. J Am Acad Dermatol, 2014, 70(1):178-186.
doi: 10.1016/j.jaad.2013.08.049
pmid: 24220724
|
| [13] |
Baddley JW, Cantini F, Goletti D, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biologi-cal therapies: an infectious diseases perspective (soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents)[J]. Clin Microbiol Infect, 2018, 24(Suppl 2):S10-S20.
doi: 10.1016/j.cmi.2017.12.025
URL
|
| [14] |
Mikulska M, Lanini S, Gudiol C, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens[I]: CD19, CD20 and CD52)[J]. Clin Microbiol Infect, 2018, 24(Suppl 2):S71-S82.
doi: 10.1016/j.cmi.2018.02.003
URL
|
| [15] |
Ekong N, Curtis H, Ong E, et al. Monitoring of older HIV-1-positive adults by HIV clinics in the United Kingdom: a national quality improvement initiative[J]. HIV Med, 2020, 21(7):409-417.
doi: 10.1111/hiv.12842
pmid: 32125760
|
| [16] |
Murdaca G, Negrini S, Pellecchio M, et al. Update upon the infection risk in patients receiving TNF alpha inhibitors[J]. Expert Opin Drug Saf, 2019, 18(3):219-229.
doi: 10.1080/14740338.2019.1577817
URL
|
| [17] |
Getahun H, Matteelli A, Abubakar I, et al. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries[J]. Eur Respir J, 2015, 46(6):1563-1576.
doi: 10.1183/13993003.01245-2015
URL
|
| [18] |
Doherty SD, van Voorhees A, Lebwohl MG, et al. National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents[J]. J Am Acad Dermatol, 2008, 59(2):209-217.
doi: 10.1016/j.jaad.2008.03.023
pmid: 18485527
|
| [19] |
Godfrey MS, Friedman LN. Tuberculosis and biologic therapies: anti-tumor necrosis factor-α and beyond[J]. Clin Chest Med, 2019, 40(4):721-739.
doi: S0272-5231(19)30056-5
pmid: 31731980
|
| [20] |
Canouï E, Launay O. History and principles of vaccination[J]. Rev Mal Respir, 2019, 36(1):74-81.
doi: S0761-8425(18)30971-9
pmid: 30579659
|
| [21] |
Dobson R, Giovannoni G. Multiple sclerosis - a review[J]. Eur J Neurol, 2019, 26(1):27-40.
doi: 10.1111/ene.13819
pmid: 30300457
|
| [22] |
Generali E, Carrara G, Kallikourdis M, et al. Risk of hospitalization for heart failure in rheumatoid arthritis patients treated with etanercept and abatacept[J]. Rheumatol Int, 2019, 39(2):239-243.
doi: 10.1007/s00296-018-4196-9
pmid: 30413926
|
| [23] |
Sbidian E, Chaimani A, Afach S, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis[J]. Cochrane Database Syst Rev, 2020, 1(1):CD011535.
|
| [24] |
Oranges CM, Schaefer DJ. Implications of rheumatic di-sease and biological response-modifying agents in plastic surgery[J]. Plast Reconstr Surg, 2016, 138(1):158e.
doi: 10.1097/PRS.0000000000002312
URL
|
